Randomized, double ‐blind, placebo‐controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy

In conclusion, this RCT was underpowered to indicate the efficacy of nanocurcumin in this clinical setti ng but could provide a considerable new translational insight to bridge the gap between the laboratory and clinical practice.

Source: Phytotherapy Research - November 14, 2018 Category: Biochemistry Authors: Afshin Saadipoor, Abolfazl Razzaghdoust, Nasser Simforoosh, Arash Mahdavi, Mohsen Bakhshandeh, Maryam Moghadam, Hamid Abdollahi, Bahram Mofid Tags: RESEARCH ARTICLE Source Type: research